The morbidity associated with obesity has exerted a tremendous burden on patients and the healthcare system globally 2 , accounting for an estimated $173 billion in medical expenditures in the United States in 2019 (ref
The retrospective cohort study by Orandi et al., recently published in The Lancet Diabetes & Endocrinology , offers compelling evidence on the effectiveness and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in kidney transplant recipients with pre-existing type 2 diabetes (1)
Outcomes: clinically relevant variables including absolute and percentage change in body weight, HbA1c reduction, cardiometabolic outcomes (e.g., major adverse cardiovascular events [MACE], hospitalizations), and adverse event incidence (e.g., gastrointestinal symptoms, hypoglycemia)
The medication is new
Pete, Gulfport, Snell Isle, Seminole, and St
Higher out-of-pocket costs for GLP-1 receptor agonists were linked to reduced adherence in type 2 diabetes patients, leading to increased hospitalizations, ED visits, and higher costs
